| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
207,851,000 |
| Market
Cap: |
11.68(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$31.86 - $59.82 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Catalent is a holding company. Through its subsidiaries, Co. has two operating and reporting segments: Biologics and Pharma and Consumer Health. The Biologics segment provides development and manufacturing for biologic proteins; cell, gene, and other nucleic acid therapies; plasmid DNA; induced pluripotent stem cells; and vaccines. The Pharma and Consumer Health segment comprises Co.'s capabilities for oral solids, softgel formulations, Zydis® fast-dissolve technologies, and gummy, soft chew, and lozenge dosage forms; formulation, development, and manufacturing platforms for oral, nasal, inhaled, and topical dose forms; and clinical trial development and supply services.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
1,000 |
1,000 |
| Total Buy Value |
$0 |
$0 |
$49,980 |
$49,980 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
1 |
1 |
| Total Shares Sold |
387 |
387 |
11,063 |
116,582 |
| Total Sell Value |
$21,749 |
$21,749 |
$512,581 |
$11,151,362 |
| Total People Sold |
1 |
1 |
12 |
18 |
| Total Sell Transactions |
1 |
1 |
25 |
69 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Okey Stephanie |
Director |
– • – |
2023-10-27 |
4 |
A |
$0.00 |
$0 |
D/D |
6,993 |
7,972 |
|
- |
|
| Mcerlane David |
Group President, BiologicsOffi |
• – – |
2023-10-25 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
19,552 |
|
44% |
|
| Ferraro Joseph Anthony |
SVP, General Counsel, CCO |
• – – |
2023-10-17 |
4 |
A |
$0.00 |
$0 |
D/D |
2,708 |
7,853 |
|
- |
|
| Hunt Patricia |
Pres. Consumer Health Div |
• – – |
2023-10-16 |
4 |
D |
$46.52 |
$1,023 |
D/D |
(22) |
11,267 |
|
- |
|
| Barg Steven |
Director |
– • – |
2023-09-10 |
4 |
A |
$0.00 |
$0 |
D/D |
718 |
718 |
|
- |
|
| Ryan Michelle R |
Director |
– • – |
2023-08-31 |
4 |
B |
$49.98 |
$49,980 |
D/D |
1,000 |
1,979 |
2.39 |
1% |
|
| Okey Stephanie |
Director |
– • – |
2023-08-28 |
4 |
A |
$0.00 |
$0 |
D/D |
979 |
979 |
|
- |
|
| Damelio Frank A |
Director |
– • – |
2023-08-28 |
4 |
A |
$0.00 |
$0 |
D/D |
979 |
979 |
|
- |
|
| Ryan Michelle R |
Director |
– • – |
2023-08-28 |
4 |
A |
$0.00 |
$0 |
D/D |
979 |
979 |
|
- |
|
| Hunt Patricia |
Pres. Consumer Health Div |
• – – |
2023-08-24 |
4/A |
A |
$0.00 |
$0 |
D/D |
106 |
11,106 |
|
- |
|
| Hawkeswood Thomas W |
Pres. Pharma Prod Delivery Div |
• – – |
2023-08-24 |
4/A |
A |
$0.00 |
$0 |
D/D |
147 |
7,412 |
|
- |
|
| Pravda Ricardo |
Chief Transformation Officer |
• – – |
2023-08-24 |
4/A |
A |
$0.00 |
$0 |
D/D |
379 |
29,522 |
|
- |
|
| Hopson Ricky |
Pres. Clinical Dev Supply Div |
• – – |
2023-08-24 |
4/A |
A |
$0.00 |
$0 |
D/D |
276 |
21,527 |
|
- |
|
| Lickfold Charles |
SVP, CIO |
• – – |
2023-08-24 |
4/A |
A |
$0.00 |
$0 |
D/D |
190 |
10,892 |
|
- |
|
| Gunther Scott |
SVP, Quality & Reg. Affairs |
• – – |
2023-08-24 |
4/A |
A |
$0.00 |
$0 |
D/D |
269 |
29,120 |
|
- |
|
| Maselli Alessandro |
President & CEO |
• • – |
2023-08-24 |
4/A |
A |
$0.00 |
$0 |
D/D |
2,071 |
86,101 |
|
- |
|
| Arnold Jonathan |
SVP, CCO & Div. Head BioP Del. |
• – – |
2023-08-24 |
4/A |
A |
$0.00 |
$0 |
D/D |
87 |
55,896 |
|
- |
|
| Fasman Steven L |
EVP & Chief Admin Officer |
• – – |
2023-08-24 |
4/A |
A |
$0.00 |
$0 |
D/D |
817 |
72,380 |
|
- |
|
| Carletti Lorenzo |
SVP Global Ops Ph & Cons Hlth |
• – – |
2023-08-24 |
4/A |
A |
$0.00 |
$0 |
D/D |
216 |
8,505 |
|
- |
|
| Gennadios Aristippos |
Group Pres. Pharma & Consumer |
• – – |
2023-08-24 |
4/A |
A |
$0.00 |
$0 |
D/D |
396 |
95,358 |
|
- |
|
| Grippo Michael J |
SVP, Strategy & Corp. Dev. |
• – – |
2023-08-24 |
4/A |
A |
$0.00 |
$0 |
D/D |
390 |
23,725 |
|
- |
|
| Pravda Ricardo |
Chief Transformation Officer |
• – – |
2023-08-24 |
4 |
S |
$44.47 |
$16,854 |
D/D |
(379) |
30,224 |
|
5% |
|
| Hawkeswood Thomas W |
Pres. Pharma Prod Delivery Div |
• – – |
2023-08-24 |
4 |
S |
$44.72 |
$6,574 |
D/D |
(147) |
7,533 |
|
5% |
|
| Hunt Patricia |
Pres. Consumer Health Div |
• – – |
2023-08-24 |
4 |
S |
$44.77 |
$4,746 |
D/D |
(106) |
11,289 |
|
5% |
|
| Arnold Jonathan |
SVP, CCO & Div. Head BioP Del. |
• – – |
2023-08-24 |
4 |
S |
$44.87 |
$3,904 |
D/D |
(87) |
57,399 |
|
5% |
|
821 Records found
|
|
Page 2 of 33 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.33 (0.58%) 
